DHA and therapeutic hypothermia in a short-term follow-up piglet model of hypoxia-ischemia: Effects on H+MRS biomarkers

PLoS One. 2018 Aug 7;13(8):e0201895. doi: 10.1371/journal.pone.0201895. eCollection 2018.

Abstract

Background: Therapeutic hypothermia has become the standard of care for newborns with hypoxic-ischemic encephalopathy in high and middle income countries. Docosahexaenoic acid (DHA) has neuroprotective properties of reducing excitotoxicity, neuroinflammation and apoptosis in rodent models. We aim to study whether post hypoxic administration of i.v. DHA will reduce H+MRS biomarkers and gene expression of inflammation and apoptosis both with and without hypothermia in a large animal model.

Methods: Fifty-five piglets were randomized to severe global hypoxia (N = 48) or not (Sham, N = 7). Hypoxic piglets were further randomized by factorial design: Vehicle (VEH), DHA, VEH + Hypothermia (HT), or DHA + HT. 5 mg/kg DHA was given intravenously 210 min after end of hypoxia. Two-way ANOVA analyses were performed with DHA and hypothermia as main effects.

Results: Cortical lactate/N-acetylaspartate (Lac/NAA) was significantly reduced in DHA + HT compared to HT. DHA had significant main effects on increasing N-acetylaspartate and glutathione in hippocampus. Therapeutic hypothermia significantly reduced the Lac/NAA ratio and protein expression of IL-1β and TNFα in hippocampus and reduced Troponin T in serum. Neuropathology showed significant differences between sham and hypoxia, but no differences between intervention groups.

Conclusion: DHA and therapeutic hypothermia significantly improve specific H+MRS biomarkers in this short-term follow up model of hypoxia-ischemia. Longer recovery periods are needed to evaluate whether DHA can offer translational neuroprotection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Biomarkers / metabolism
  • Brain / diagnostic imaging
  • Brain / drug effects
  • Brain / metabolism
  • Brain / pathology
  • Combined Modality Therapy
  • Disease Models, Animal
  • Docosahexaenoic Acids / pharmacology*
  • Female
  • Follow-Up Studies
  • Hypothermia, Induced*
  • Hypoxia-Ischemia, Brain / diagnostic imaging
  • Hypoxia-Ischemia, Brain / metabolism*
  • Hypoxia-Ischemia, Brain / pathology
  • Hypoxia-Ischemia, Brain / therapy*
  • Male
  • Neuroprotective Agents / pharmacology*
  • Proton Magnetic Resonance Spectroscopy
  • Random Allocation
  • Time Factors
  • Treatment Outcome

Substances

  • Biomarkers
  • Neuroprotective Agents
  • Docosahexaenoic Acids

Grants and funding

This work was supported by the Norwegian SIDS and Stillbirth Society: https://www.lub.no/norwegian-sids-and-stillbirth-society; Laerdal Foundation: https://laerdalfoundation.org/; and South East Norway Regional Health Authority: https://www.helse-sorost.no/south-eastern-norway-regional-health-authority, Grant number: 39570.